- Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2). Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O'Connell P, Izquierdo M, Pedroncelli AM, Pivonello R. Pituitary. 2022 Dec;25(6):959-970. doi: 10.1007/s11102-022-01280-6. Epub 2022 Oct 11.

- Efficacy and safety of osilodrostat in paraneoplastic Cushing's syndrome: a real-world multicenter study in France. Dormoy A, Haissaguerre M, Vitellius G, Cao CD, Geslot A, Drui D, Lasolle H, Vieira-Pinto O, Salenave S, François M, Puerto M, Boullay HD, Mayer A, Rod A, Laurent C, Chanson P, Reznik Y, Castinetti F, Chabre O, Baudin E, Raverot G, Tabarin A, Young J. J Clin Endocrinol Metab. 2022 Dec 6:dgac691. doi: 10.1210/clinem/dgac691. Online ahead of print.PMID: 36470583

- Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pivonello R, Zacharieva S, Elenkova A, Tóth M, Shimon I, Stigliano A, Badiu C, Brue T, Georgescu CE, Tsagarakis S, Cohen F, Fleseriu M. Pituitary. 2022 Dec;25(6):911-926. doi: 10.1007/s11102-022-01263-7. Epub 2022 Sep 9.PMID: 36085339 

- Cushing's disease: role of preoperative and primary medical therapy. Castinetti F. Pituitary. 2022 Oct;25(5):737-739. doi: 10.1007/s11102-022-01244-w. Epub 2022 Jul 2. PMID: 35780261 Review. 

- Is Desmopressin Useful in the Evaluation of Cushing Syndrome? Castinetti F, Lacroix A.J Clin Endocrinol Metab. 2022 Nov 23;107(11):e4295-e4301. doi: 10.1210/clinem/dgac533. PMID: 36103267 Review.

- Medical management of Cushing's disease: When and how? Castinetti F.J Neuroendocrinol. 2022 Aug;34(8):e13120. doi: 10.1111/jne.13120. Epub 2022 Mar 29.PMID: 35348261 Review.

- How best to monitor the specific side effects of medical treatments of Cushing's disease. Castinetti F.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101718. doi: 10.1016/j.beem.022.101718. Epub 2022 Nov 14.

- Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Tabarin A, Assié G, Barat P, Bonnet F, Bonneville JF, Borson-Chazot F, Bouligand J, Boulin A, Brue T, Caron P, Castinetti F, Chabre O, Chanson P, Corcuff JB, Cortet C, Coutant R, Dohan A, Drui D, Espiard S, Gaye D, Grunenwald S, Guignat L, Hindie E, Illouz F, Kamenicky P, Lefebvre H, Linglart A, Martinerie L, North MO, Raffin-Samson ML, Raingeard I, Raverot G, Raverot V, Reznik Y, Taieb D, Vezzosi D, Young J, Bertherat J.Ann Endocrinol (Paris). 2022 Apr;83(2):119-141. doi: 10.1016/j.ando.2022.02.001. Epub 2022 Feb 19.PMID:35192845.

- Medical management of Cushing's disease: When and how? Castinetti F.J Neuroendocrinol. 2022 Aug;34(8):e13120. doi: 10.1111/jne.13120. Epub 2022 Mar 29.PMID: 35348261 Review.

- Cushing's disease: role of preoperative and primary medical therapy. Castinetti F.Pituitary. 2022 Jul 2. doi: 10.1007/s11102-022-01244-w. Online ahead of print.PMID: 35780261 Review.

- Aggressive corticotroph tumors and carcinomas. Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G.J Neuroendocrinol. 2022 Aug;34(8):e13169. doi: 10.1111/jne.13169. Epub 2022 Aug 18.PMID: 35979732 Review.

- Consensus on diagnosis and management of Cushing's disease: a guideline update. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK.. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. PMID: 34687601

- Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy. Amodru V, Brue T, Castinetti F. Endocrinol Diabetes Metab Case Rep. 2021 Dec 1;2021:21-0071. doi: 10.1530/EDM-21-0071. Online ahead of print. PMID: 34877930

- Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. Wolf P, Marty B, Bouazizi K, Kachenoura N, Piedvache C, Blanchard A, Salenave S, Prigent M, Jublanc C, Ajzenberg C, Droumaguet C, Young J, Lecoq AL, Kuhn E, Agostini H, Trabado S, Carlier PG, Fève B, Redheuil A, Chanson P, Kamenický P. J Clin Endocrinol Metab. 2021 Nov 19;106(12):3505-3514. doi: 10.1210/clinem/dgab556. PMID: 34333603.

- Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. Reincke M, Albani A, Assie G, Bancos I, Brue T, Buchfelder M, Chabre O, Ceccato F, Daniele A, Detomas M, Di Dalmazi G, Elenkova A, Findling J, Grossman AB, Gomez-Sanchez CE, Heaney AP, Honegger J, Karavitaki N, Lacroix A, Laws ER, Losa M, Murakami M, Newell-Price J, Pecori Giraldi F, Pérez-Rivas LG, Pivonello R, Rainey WE, Sbiera S, Schopohl J, Stratakis CA, Theodoropoulou M, van Rossum EFC, Valassi E, Zacharieva S, Rubinstein G, Ritzel K. Eur J Endocrinol. 2021 Mar;184(3):P1-P16. doi: 10.1530/EJE-20-1088. PMID: 33444221

- Letter to the Editor: "USP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors". Lasolle H, Raverot G.J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3285-e3286. doi: 10.1210/clinem/dgab217.PMID: 33822961

- Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. Castinetti F, Amodru V, Brue T. Clin Endocrinol (Oxf). 2021 Jul 5. doi: 10.1111/cen.14551. Online ahead of print. PMID: 34219265

- Pre-term birth in women exposed to Cushing's disease: the baby-cush study. Hochman C, Cristante J, Geslot A, Salenave S, Sonnet E, Briet C, Bachelot A, Chevalier N, Gilly O, Brue T, Hadjadj S, Kerlan V, Chanson P, Vezzosi D, Chabre O, Drui D, Castinetti F. Eur J Endocrinol. 2021 Mar;184(3):469-476. doi: 10.1530/EJE-20-1224. PMID: 33486470


- Letter to the Editor: "Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI".
Castinetti F, Graillon T, Dufour H, Brue T. J Clin Endocrinol Metab. 2019 Dec 1;104(12):5791-5792.

- High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry.
Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R, Tóth M, Zacharieva S, Webb SM, Tsagarakis S, Chanson P, Pfeiffer M, Droste M, Komerdus I, Kastelan D, Maiter D, Chabre O, Franz H, Santos A, Strasburger CJ, Trainer PJ, Newell-Price J, Ragnarsson O. Eur J Endocrinol. 2019 Nov;181(5):461-472.

- Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue.
Maurice F, Gaborit B, Vincentelli C, Abdesselam I, Bernard M, Graillon T, Kober F, Brue T, Castinetti F, Dutour A.J Am Coll Cardiol. 2018 Oct 30;72(18):2276-2277.
 

 - A 12-month phase 3 study of pasireotide in Cushing's disease. 

Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM; Pasireotide B2305 Study Group.

N Engl J Med. 2012 Mar 8;366(10):914-24.

 - The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. 

Castinetti F, Brue T, Conte-Devolx B.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):295-9.

- Cushing's disease.

Castinetti F, Morange I, Conte-Devolx B, Brue T.

Orphanet JRare Dis. 2012 Jun 18

 - Management of hyperglycaemia in Cushing's disease: Experts' proposals on the use of pasireotide. 

Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, Delemer B, Tabarin A, Bisot-  Locard  S,Vergès B.

Diabetes Metab. 2012 Dec 7.

 - The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. 

Valassi E, Santos A, Yaneva M, Toth M, Strasburger Cj, Chanson P, Wass Ja, Chabre O, Pfeifer M, Feelders Ra, Tsagarakis S, Trainer Pj, Franz H, Zopf K, Zacharieva S, Lamberts Sw, Tabarin A, Webb Sm; Ercusyn Study Group.

Eur. J. Endocrinol. 2011 Sep;165(3):383-92.

 - Medical treatment of Cushing’s syndrome: glucocorticoid receptor antagonists and mifepristone. 

Castinetti F., Conte-Devolx B., Brue T.

Neuroendocrinol. 2010;92 Suppl 1:125-130.

- Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.

Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C.

Clin. Pharmacokinet. 2010 July 1;49(7):455-63.

- Merits and pitfalls of mifepristone in Cushing’s syndrome.

Castinetti F., Fassnacht M., Johanssen S., Terzolo M., Bouchard P., Chanson P., Do Cao C., Morange I., Picó A., Ouzounian S., Young J., Hahner S., Brue T., Allolio, B., Conte-Devolx B.

Eur. J. Endocrinol. 2009, Jun;160(6):1003-10.

- A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease.

Castinetti F, Martinie M, Morange I, Dufour H, Sturm N, Passagia Jg, Conte-Devolx B, Chabre O, Brue T.

J. Clin. Endocrinol. Metab. 2009 Jun;94(6):1897-903.

- Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease.

Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T.

Eur. J. Endocrinol. 2008;158(1):91-99.

- Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH dependent Cushing’s syndrome.

Castinetti F, Morange I, Dufour H, Jaquet P, Conte-Devolx B, Girard N, Brue T.

Eur. J. Endocrinol. 2007;157(3):271-77.

- Misexpression of Brg1 and HDAC2 in Cushing disease, a condition of glucocorticoid resistance.

Bilodeau S., Vallette-Kasic S., Figarella-Branger D., Brue T., Berthelet F., Lacroix A., Batista D., Stratakis C., Hanson J., Meij B., Drouin J.

Genes Dev. 2006;20(20):2871-86.